No Detail Found!

Patterns of Antiallergic Drug Consumption in Kyrgyzstan: A Nationwide ATC/DDD-Based Analysis of Antihistamines and Glucocorticosteroids (2024-2025)

Author(s)
Esenalieva Asel Okenovna Institute of Chemistry and Phytotechnology, National Academy of Science of Kyrgyz Republic, Kyrgyz Republic, Bishkek, Chui Avenue, 265a, Kyrgyzstan
Murzabaeva Elvira Bolotbekovna Department of Pharmaceutical Sciences, Faculty of Medicine, Ala-Too International University, Bishkek, Ankara st. 1/8, Kyrgyzstan
Ismailov Isabek Zailidinovich Institute of Chemistry and Phytotechnology, National Academy of Science of Kyrgyz Republic, Kyrgyz Republic, Bishkek, Chui Avenue, 265a, Kyrgyzstan
Sabirova Tamara Semenovna Department of Pharmacognosy and Chemistry of Medicines, Kyrgyz State Medical Academy named after I.K. Akhunbaev, Kyrgyz Republic, Bishkek, Akhunbaev st. 92, Kyrgyzstan
Barbieva Elnura Bekbolotovna Institute of Chemistry and Phytotechnology, National Academy of Science of Kyrgyz Republic, Kyrgyz Republic, Bishkek, Chui Avenue, 265a, Kyrgyzstan
Abstract
Objectives: Antiallergic drugs, including antihistamines and glucocorticosteroids, are widely used in the allergic diseases and inflammatory conditions. Monitoring their consumption is essential for assessing rational use, accessibility and adherence to clinical guidelines. In Central Asian countries, including the Kyrgyz Republic, up-to-date nationwide data on antiallergic drug utilization remain limited. This study aimed to analyze consumption patterns of antihistamines and glucocorticosteroids in Kyrgyzstan during 2024-2025 using the WHO-recommended ATC/DDD methodology. Methods: A retrospective nationwide drug utilization study was conducted based on official pharmaceutical distribution and registry data. All systemic antihistamines (ATC code R06A) and glucocorticosteroids were included in the analysis. Drug consumption was assessed using Defined Daily Doses (DDD), DDDs per 1,000 inhabitants per year (DID) and Packages per Inhabitant per Year (PIY). Consumption structure by International Nonproprietary Names (INNs) and temporal trends were analyzed. Results: Between 2024 and 2025, antiallergic drug use showed divergent patterns depending on the indicator applied. Total antihistamine consumption increased from 34,350,864 DDDs to 41,271,951 DDDs (1.2-fold growth), while population-adjusted exposure declined from 9 DID to 7 DID. Loratadine, cetirizine and levocetirizine remained the most frequently used agents , with cetirizine showing a notable consumption increase from 4.36 to 6.85 million DDDs. Systemic glucocorticosteroids followed a downward trajectory, with total volume decreasing from 10,674,561 DDDs to 9,451,298 DDDs and population exposure falling sharply from 3.79 DID to 0.82 DID. This reflects a pronounced contraction driven primarily by a structural withdrawal from dexamethasone (from 7.02 million to 481,369 DDDs). Conclusion: National ATC/DDD data for 2024-2025 indicate measurable changes in the composition and intensity of antiallergic therapy in Kyrgyzstan. Second-generation antihistamines continue to dominate outpatient treatment, while systemic corticosteroid use has contracted. From a public health standpoint, these patterns demonstrate favorable shifts toward aligned guideline prescribing and post-pandemic clinical stabilization, but highlight the critical importance of continuous, integrated pharmacoepidemiological surveillance to prevent potential access limitations and to support clinical stewardship.
Publication Details
Page(s) 138-145
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 6, Year: 2026

Request the full text from PASTIC

Keywords
Antiallergic Drugs, Drug Pharmacoepidemiology, Glucocorticosteroids, Kyrgyzstan, Antihistamines
References
Bousquet J. . .Highlights and recent developments in allergic diseases in EAACI journals. ” Clinical and Translational Allergy, 10(2020) : 1-11.
Iftikhar J. .2024 .Shifting perspectives: Diphenhydramine usage in anaphylaxis and urticaria across United States emergency departments. ” Annals of Allergy, Asthma and Immunology, 09(2024) : S11.
Charoo N.A. .2024 .Biowaiver monograph for immediaterelease solid oral dosage forms: Fexofenadine. ” Journal of Pharmaceutical Sciences, 02(2024) : 1201-1213.
Kapoor Y.,Kumar K. .2019 .Structural and clinical impact of anti-allergy agents: An overview. Bioorganic Chemistry, 103351 : .
Hailesilase G.G. .2024 .WHO/INRUD prescribing indicators with a focus on antibiotics utilization patterns at outpatient department of Adigrat General Hospital, Tigrai, Ethiopia: A retrospective cross-sectional study. ” Antimicrobial Resistance and Infection Control, 13(1) : .
Desai R.J. .2024 .Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED). ” BMJ, 384 : .
Bindel L.J.,Seifert R. . .” NaunynSchmiedeberg's Archives of Pharmacology. , 397(2024) : 1123-1135.
Cabral C.,JAC-Antimicrobial Resistance .2024 .Influences on use of antibiotics without prescription by the public in low- and middle-income countries: A systematic review and synthesis of qualitative evidence. , 6(5) : .
Schaller M.C. .2024 .Is the shift in treatment patterns toward new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990-. Expert Review of Pharmacoeconomics and Outcomes Research, 2367445(2025) : 35-45.
Tang L. .2024 .A point prevalence survey and monitoring indicator research on the second batch of national key monitoring and rational use drugs. , 1416010 : .
.2023 .WHO model list of essential medicines. 23rd Edn, : .
Niëns L.M. . .Pharmaceutical pricing policies: A new methodology for comparing affordability of medicines.” Bulletin of the World Health Organization. , 90(2012) : 219-227.
Mendis S. . .The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. ” Bulletin of the World Health Organization, 85(2007) : 279-288.
Palafox B. .2021 .Inequality in access to medicines in lowand middle-income countries: A systematic review. International Journal for Equity in Health, 20(1) : .
.2019 .World Health Organization Regional Office for Europe. Improving access to quality essential medicines in Kyrgyzstan. , : .
Malaya E. .2024 .Medication adherence in allergic diseases and asthma in Kyrgyzstan: Financial reasons for poor uptake. , 1488665 : .
Tabyshova A. .2022 .Medication availability and economic barriers to adherence in COPD and asthma patients in Kyrgyzstan.”NPJ Primary Care Respiratory Medicine. , 32(1) : .
Stolbrink M. .2024 .Availability, cost and affordability of chronic respiratory disease medicines in low-income and middle-income countries. ” BMJ Global Health, 9 : .
Nations United .2024 .Office on Drugs and Crime. Study on the availability of controlled pharmaceutical drugs to treat severe pain in the Kyrgyz Republic. , : .
Wirtz V.J. .2017 .Essential medicines for universal health coverage.” The Lancet. , 6736(16) : 31599-9.
Koala D. .2021 .Factors influencing drug consumption and prediction methods: A review. ” arXiv, 2109 : 11779.
.2024 .. [24] CADAP. Systematisation report of the National Drug Policy Dialogue including Kyrgyzstan. EU-CADAP, : .
.2023 .Global antimicrobial resistance and use Surveillance System (GLASS) report 2023. , : .
Ivashchenko A.A. . .Drug utilization patterns of antihistamines in the Russian Federation using ATC/DDD methodology. International Journal of Risk and Safety in Medicine, 30(2019) : 123-131.
Tulegenova A. . .Drug utilization review of antihistamines in outpatient practice in Kazakhstan. Medical Journal of Kazakhstan, no. 4, (2018) : 45-50.
Rakhimova G.N. and N.K.,Yuldasheva G.N. and N.K. . .Pharmacotherapy patterns of allergic diseases in Uzbekistan: Focus on antihistamines. ” Bulletin of Medical Sciences (Uzbekistan), 3(2017) : 32-37.
Bousquet J. .2019 .Next-generation ARIA care pathways for allergic rhinitis and asthma multimorbidity. ” Allergy, 74(11) : 2084-2102.
Zhuravleva M.V. . .Drug utilization trends of systemic corticosteroids in the Russian Federation before and after the COVID-19 pandemic. Pharmacoepidemiology and Drug Safety, 32(2023) : 1021-1029.
Tulegenova A. . .Changes in systemic corticosteroid prescribing patterns in Kazakhstan in the post-COVID period. ” Central Asian Journal of Medicine, no. 2, (2023) : 45-52.
Elseviers M. .2023 .Drug utilization research in Eastern Europe: Post-pandemic shifts and regulatory challenges. , 1189021 : .
.2022 .Corticosteroids for COVID-19: Living guidance-post-pandemic considerations. , : .
Holloway K. .2021 .Surveillance of antimicrobial and corticosteroid use: Balancing access and rational use in lowand middle-income countries. ” WHO Drug Information, 35(2) : .
0

Citations

0

Downloads

17

Views